New York, New York (PRWEB) March 23, 2014
Biomet hip lawsuits (http://www.consumerinjurylawyers.com/biomet-magnum-hip-replacement) filed on behalf of individuals who were allegedly injured by the M2a Magnum Hip Replacement System continue to mount in the federal multidistrict litigation underway in U.S. District Court, Northern District of Indiana, Bernstein Liebhard LLP reports. According to court documents, at least 1,268 Biomet hip replacement claims were pending in the proceeding as of March 13, 2014. More than 120 claims have been filed in Biomet hip replacement litigation since a previous update was issued by the Court in February. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)
“Our Firm continues to receive inquiries from Biomet hip replacement patients who allegedly suffered serious and debilitating complications due to the M2a hip system. It is not surprising that the number of filings has surpassed 1,200,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including clients who have filed Biomet hip lawsuits. The Firm continues to offer free and confidential legal consultations to individuals who may have been injured by the Biomet M2a Magnum Hip Replacement System.
Biomet Hip Lawsuit Settlement
All of the Biomet hip lawsuits pending in the Northern District of Indiana allege that the metal-on-metal design of the M2a Magnum hip can result in a dangerous accumulation of metal ions in patients’ tissue and blood stream. Plaintiffs further allege that this can cause a number painful complications, including metallosis, chronic pain, and loss of mobility and premature failure of the hip, all of which may necessitate removal and replacement of the device.
The U.S. Food & Drug Administration (FDA) has determined that metal-on-metal hips are more likely to fail prematurely than those manufactured of other materials. In January 2013, the agency advised recipients of such hip implants to seek medical attention if they experience any symptoms that could indicate a problem with the device. At the same time, the FDA said it was proposing new regulations that would subject metal-on-metal hips to greater regulatory scrutiny.
According to court documents, a Biomet hip replacement settlement proposal was announced in the federal litigation on February 3, 2014, which could ultimately resolve hundreds of claims involving the M2a Magnum hip. To participate in the settlement program, plaintiffs must file their Biomet hip lawsuits no later than April 15, 2014. According to court documents, plaintiffs who received one of the affected Biomet hip replacements as part of an initial surgery that was rectified more than 180 days after it was implanted will be eligible for a base award of $200,000.
Recipients of an M2a Magnum hip may be entitled to file their own Biomet hip lawsuit if they experienced serious and debilitating complications allegedly associated with its metal-on-metal design. Find out more about filing a Biomet hip replacement claim by visiting Bernstein Liebhard LLP’s website. To arrange for a free case review, call 800-511-5092 to speak with a member of our legal staff.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP